FDAsafety guidance66% confidence
Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd. - 731020 - 07/10/2026
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Sun Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Cardiovascular · Statin
- Sub-indication
- General
Related signal: FDA Accepts Supplement for Rosuvastatin Calcium by Sun Pharma